newsfilter
← Latest News
GlobeNewswire·

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange Book Listable